What is NeRRe Therapeutics?
Founded in 2012 as a strategic spin-out from GSK, NeRRe Therapeutics operates at the intersection of neuroscience and respiratory medicine. The company is primarily focused on the development of orvepitant, a potent neurokinin-1 receptor antagonist. This asset is currently being evaluated for its efficacy in treating chronic cough associated with idiopathic pulmonary fibrosis, a rare and terminal lung condition. By leveraging deep expertise in receptor pharmacology, NeRRe Therapeutics aims to transform the standard of care for patients who have historically lacked effective therapeutic interventions. The company's operational model emphasizes rigorous clinical validation and a focused approach to drug development, ensuring that its lead assets are positioned for potential regulatory approval and commercial viability within the global pharmaceutical market.
How much funding has NeRRe Therapeutics raised?
NeRRe Therapeutics has raised a total of $36.3M across 2 funding rounds:
Series A
$8.1M
Series B
$28.2M
Series A (2012): $8.1M, investors not publicly disclosed
Series B (2017): $28.2M led by Advent Life Sciences, OrbiMed, Fountain Healthcare Partners, Forbion, and Novo A/S
Key Investors in NeRRe Therapeutics
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term life sciences investments.
Advent Life Sciences
Advent Venture Partners LLP is a UK-based venture capital firm specializing in early-stage and growth-stage investments within the life sciences and technology sectors.
What's next for NeRRe Therapeutics?
With the recent influx of capital, NeRRe Therapeutics is well-positioned to accelerate its clinical development programs. The strategic roadmap involves advancing orvepitant through critical trial phases, with a focus on generating robust data to support future regulatory filings. As the company transitions from early-stage development to more advanced clinical evaluation, the management team will likely prioritize operational scaling and potential strategic partnerships to maximize the therapeutic and commercial reach of its pipeline. The continued support from high-profile life sciences investors provides the necessary financial runway to navigate the complexities of late-stage drug development, ensuring that the firm remains a leader in the specialized field of cough hypersensitivity and respiratory disease management.
See full NeRRe Therapeutics company page
